Lead Sponsor

Vascular Biogenics Ltd. operating as VBL Therapeutics

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•1. Subjects must have a histologically confirmed diagnosis of glioblastoma multiforme or gliosarcoma;
•2. Measurable disease by RANO criteria;
•3. Disease progression or recurrence following standard of care treatment with temozolomide and radiation;
•4. An interval of at least 4 weeks between prior surgical resection and study enrollment;
•5. An interval of at least 12 weeks between prior radiotherapy or at least 4 weeks from prior chemotherapy, and enrollment in this protocol;
•6. Recovered to Grade 1 or less from the toxic effects of any earlier intervention;
•7. Karnofsky performance status \> 60%

•1. Prior anti-angiogenic therapy including VEGF sequestering agents (ie bevacizumab, aflibercept, etc) or VEGFR inhibitors (cediranib, pazopanib, sunitinib, sorafenib, etc);
•2. Prior stereotactic radiotherapy;
•3. Active infection;
•4. Evidence of CNS haemorrhage CTCAE grade 2 or above on baseline MRI;
•5. Subjects who suffered from an acute cardiac event within the last 12 months;
•6. Subjects with active vascular disease, either myocardial or peripheral;
•7. Subjects with proliferative and/or vascular retinopathy;
•8. Subjects with known active second malignancy;

Related studies

NCT05303467 · Glioblastoma Multiforme, Recurrent Glioblastoma

NCT07464925 · Glioblastoma Multiforme of Brain, Glioma, and more

NCT05271240 · Glioblastoma, Glioblastoma Multiforme, and more

NCT01269853 · Glioblastoma Multiforme, Anaplastic Astrocytoma

NCT05954858 · Glioma, Malignant, Glioblastoma, and more

Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme